ArticlePloS one2026
Analysis of the antimicrobial activity of zinc oxide nanoparticles against drug-resistant bacteria and their applications in the disinfection process.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Nanotechnology-Enabled Strategies to Overcome Antibiotic Resistance in Respiratory Infections: Mechanisms, Platforms, and Translational Challenges.Biomedicines · 2026Review
- Green synthesis of ZnO/FeRSC advances · 2026Article
- Biosynthesis of antibacterial zinc oxide nanoparticles from endophytic Streptomyces werraensis.Scientific reports · 2026Article
- Eco-Friendly Bioinspired Synthesis and Environmental Applications of Zinc Oxide Nanoparticles Mediated by Natural Polysaccharide Gums: A Sustainable Approach to Nanomaterials Fabrication.Nanomaterials (Basel, Switzerland) · 2026Review
- Susceptibility of the Oral Commensal BacteriumInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rise in antimicrobial resistance has necessitated the exploration of novel antimicrobial agents. Zinc oxide nanoparticles (ZnO-NPs) have gained prominence due to their biocompatibility, minimal toxicity, and potent antimicrobial properties. This study evaluates the antimicrobial activity of ZnO-NPs synthesized from Phoenix dactylifera root extract and their potential applications in disinfection. METHODOLOGY: ZnO-NPs were synthesized using an eco-friendly method involving Phoenix dactylifera root extract and zinc acetate at varied concentrations and ratios, followed by annealing. The nanoparticles were characterized and assessed for antimicrobial activity against a spectrum of bacterial and fungal isolates using microtiter broth dilution, disc diffusion, and pour plate assays. Disinfection efficacy was evaluated on water samples and surfaces. Additionally, the impact of ZnO-NPs on acid-fast bacilli (AFB) isolates was examined using VersaTrek Mycobottles.
resultsZnO-NPs exhibited potent antimicrobial activity against Gram-positive and Gram-negative bacteria, with minimum inhibitory concentrations (MICs) ranging from 9.7 to 310 µg/mL. Disc diffusion assays revealed larger inhibition zones in Gram-positive bacteria compared to Gram-negative strains, with MRSA showing the widest zone (24 mm). ZnO-NPs significantly reduced colony-forming units (CFU) on water and surfaces, achieving complete bacterial inhibition on laboratory benches within 20 minutes. The nanoparticles demonstrated bactericidal effects against AFB isolates, highlighting their broad-spectrum efficacy.
conclusionThe study underscores the potential of ZnO-NPs as a versatile antimicrobial agent effective against MDR (multidrug-resistant) pathogens and environmental contaminants. Their rapid action and broad-spectrum activity make them suitable for disinfection in clinical and environmental settings. Future research could explore synergistic combinations with traditional antimicrobials to enhance efficacy against infections that are resistant to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.